We are BarentsKrans

Our lawyers and notaries provide specialist legal services on a national and international scale. Our expertise covers litigation, advice and transactions. BarentsKrans is committed to quality; we deliver high levels of work and success rates. It also means that you can count on us: we work together with you throughout to achieve the best possible outcome. We call this ‘being dedicated’.

Watch video

News & publications

Corporate / M&AMergers and acquisitions

BarentsKrans advises on the sell side of the acquisition of Sanidump

BK has advised on the sell side of the acquisition of Sanidump by the FG-group, the holding company of the Dutch franchise formulas Sanisale.com, Keukensale.com, Sanistunter and Keukenstunter. Sanidump operates 41 megastores and is the largest and fastest growing independent sanitary shop in the Netherlands and has over 24 years of experience in that field.
Read more ›
| Marleen van den Horst
Life sciencesPatents and technologyPharma & regulatory

Pharma update | Dutch Court of Appeal: Pemetrexed patent Eli Lilly valid and infringed

In its judgment of 27 October 2020, the Court of Appeal of The Hague found that the generic pemetrexed tromethamine product of Fresenius Kabi Nederland B.V. (“Fresenius”) infringes EP 1 313 508 (‘EP‘508’), held by Eli Lilly and Company (“Lilly”). Yet again a turn of events in Dutch case law, where this issue has been
Read more ›
| Marleen van den Horst
Life sciencesPatents and technologyPharma & regulatory

Pharma update | AstraZeneca ordered to compensate damage health insurer Menzis for enforcing invalid patent

In a groundbreaking judgment of 14 October 2020, the District Court of The Hague ruled that AstraZeneca AB (‘AstraZeneca’) must compensate health insurer Menzis Zorgverzekeraar NV (‘Menzis’) for having enforced a patent that was later invalidated. AstraZeneca owned European patent EP 0 907 364 (“EP 364”) for a sustained-release (XR) formulation of quetiapine, an active
Read more ›
| Jaap Bremer
Life sciencesPharma & regulatory

Pharma update | Cross-border preliminary injunction granted regarding deferasirox

At the request of Novartis the Provisions Judge of the District Court of The Hague granted a preliminary injunction against Mylan BV for the alleged imminent infringement of Novartis’ paediatric extension (‘PE’) of Dutch SPC 300248 (‘SPC ‘248’) based on EP 0 914 118 (‘EP ‘118’).The product at issue contains deferasirox as the active ingredient
Read more ›

Contact

General

T. 070 – 376 06 06
E. info@barentskrans.nl

Visiting address

Lange Voorhout 3
2514 EA Den Haag

Postal address

Postbus 30457
2500 GL Den Haag


More details